Ralph DeMasi

5.0k total citations · 1 hit paper
82 papers, 3.7k citations indexed

About

Ralph DeMasi is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Ralph DeMasi has authored 82 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Infectious Diseases, 37 papers in Virology and 27 papers in Hepatology. Recurrent topics in Ralph DeMasi's work include HIV/AIDS drug development and treatment (41 papers), HIV Research and Treatment (37 papers) and HIV/AIDS Research and Interventions (31 papers). Ralph DeMasi is often cited by papers focused on HIV/AIDS drug development and treatment (41 papers), HIV Research and Treatment (37 papers) and HIV/AIDS Research and Interventions (31 papers). Ralph DeMasi collaborates with scholars based in United States, United Kingdom and France. Ralph DeMasi's co-authors include Miklos Salgo, Michael Greenberg, Jain Chung, John Bartlett, Joseph Quinn, Franck Rousseau, John Delehanty, Thomas J. Matthews, Dani P. Bolognesi and Jacob Lalezari and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Hepatology.

In The Last Decade

Ralph DeMasi

79 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

2003 716 citations Jacob Lalezari, Sharon Walmsley et al. profile →

Peers

Countries citing papers authored by Ralph DeMasi

Since Specialization

Citations

This map shows the geographic impact of Ralph DeMasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph DeMasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph DeMasi more than expected).

Fields of papers citing papers by Ralph DeMasi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph DeMasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph DeMasi. The network helps show where Ralph DeMasi may publish in the future.

Co-authorship network of co-authors of Ralph DeMasi

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph DeMasi. A scholar is included among the top collaborators of Ralph DeMasi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph DeMasi. Ralph DeMasi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective 2024 ·International Journal of Antimicrobial Agents ·Ann M. Buchanan, Adrie Bekker, Hardik Chandasana, Ralph DeMasi, (unknown), Terry B. Ernest, (unknown), Sherene Min, Theodore Ruel, Lionel Tan	1
2	Responding to the Call to Action: Framework to Accelerate Clinical Data Generation for Antiretroviral Use in Pregnant Individuals with HIV 2024 ·Infectious Diseases and Therapy ·Vani Vannappagari, Scott McCallister, (unknown), Mark Bush, Dinesh Stanislaus, (unknown), (unknown), Nneka Nwokolo, Ana M. Puga, (unknown), Farzaneh Salem, Ralph DeMasi, Nassrin Payvandi, (unknown), H Garges, Annemiek de Ruiter	3
3	Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection. 2017 ·PubMed ·Gianpiero D’Offizi, Calogero Cammà, Chiara Taibi, Michael Schlag, Karin Weber, (unknown), Ralph DeMasi, (unknown), James Witek, Raffaella Lionetti	4
4	Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study 2014 ·Liver International ·Thomas Berg, Pietro Andreoné, Stanislas Pol, Stuart K. Roberts, Zobair M. Younossi, M. Diago, Eric Lawitz, Roberto Focaccia, Graham R. Foster, Andrzej Horban, Isabelle Lonjon‐Domanec, Ralph DeMasi, Gastón Picchio, Donghan Luo, Sandra De Meyer, Stefan Zeuzem	5
5	Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program 2014 ·Journal of Hepatology ·Massimo Colombo, Simone I. Strasser, Christophe Moreno, Paulo Roberto Abrão Ferreira, Petr Urbánek, Inmaculada Fernández, (unknown), Adrian Streinu‐Cercel, (unknown), Wafae Iraqi, Ralph DeMasi, Andrew F. Hill, Isabelle Lonjon‐Domanec, Heiner Wedemeyer	24
6	798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY 2013 ·Journal of Hepatology ·(unknown), Kosh Agarwal, Yves Horsmans, William Sievert, Ewa Janczewska, Stefan Zeuzem, (unknown), Robert S. Brown, C. Hézode, M. Rizzetto, Raymundo Paraná, Sandra De Meyer, Ralph DeMasi, (unknown), (unknown)	6
7	Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C 2013 ·Gut ·M. Colombo, Inmaculada Fernández, (unknown), Paulo Roberto Abrão Ferreira, Simone I. Strasser, Petr Urbánek, Christophe Moreno, Adrian Streinu‐Cercel, (unknown), Wafae Iraqi, Ralph DeMasi, Andrew Hill, J.M. Läuffer, Isabelle Lonjon‐Domanec, Heiner Wedemeyer	42
8	Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96 2011 ·HIV Clinical Trials ·Jan Fourie, Jason Flamm, (unknown), (unknown), Peré Domingo, Adriano Lazzarin, Juan Ballesteros, Néstor Sosa, Tom Van de Casteele, Ralph DeMasi, Sabrina Spinosa‐Guzman, Ludo Lavreys	9
9	Adherence to Enfuvirtide and Its Impact on Treatment Efficacy 2008 ·AIDS Research and Human Retroviruses ·Jürgen K. Rockstroh, Edwin DeJesus, (unknown), Cynthia Wat, A Bertasso, Emily Labriola–Tompkins, (unknown), (unknown), (unknown), Timothy D. Wilkinson, James Thommes, Lucy Rowell, Ralph DeMasi, Miklos Salgo	4
10	Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients 2008 ·HIV Clinical Trials ·David H. Wright, (unknown), Eliot Godofsky, Sharon Walmsley, Emily Labriola–Tompkins, (unknown), (unknown), (unknown), (unknown), Jain Chung, Lucy Rowell, Ralph DeMasi, Neil M.H. Graham, Miklos Salgo	10
11	Seeking Ethical Designs for HIV Clinical Trials in Treatment-Experienced Patients: An Industry Perspective 2006 ·AIDS Research and Human Retroviruses ·Douglas L. Mayers, Jain Chung, Veronika Kohlbrenner, David B. Hall, Ralph DeMasi, Dietmar Neubacher, Neil Buss, Miklos Salgo	1
12	An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults 2006 ·AIDS ·John Bartlett, Michael Fath, Ralph DeMasi, Ashwaq Hermes, Joseph Quinn, Elsa Mondou, Franck Rousseau	189
13	T‐1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide‐Containing Treatment Regimen 2005 ·The Journal of Infectious Diseases ·Jacob Lalezari, Nicholaos Bellos, (unknown), Gary Richmond, Calvin Cohen, Robert A. Myers, David H. Henry, Claire Raskino, (unknown), (unknown), Ying Zhang, (unknown), Michael Greenberg, Ralph DeMasi, G. Diego Miralles, (unknown)	78
14	Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients 2003 ·Journal of Clinical Virology ·David A. Wheeler, Jacob Lalezari, J Michael Kilby, Joseph Wheat, John Delehanty, Ralph DeMasi, Indravadan H. Patel, Miklos Salgo	18
15	Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults 2001 ·AIDS ·John Bartlett, Ralph DeMasi, Joseph Quinn, (unknown), Franck Rousseau	311
16	Health-related Quality of Life and Virologic outcomes in an HIV Clinic 2000 ·Quality of Life Research ·Stephanie Call, Joshua C. Klapow, Kenneth Stewart, Andrew O. Westfall, (unknown), Ralph DeMasi, Robert M. Centor, Michael S. Saag	102
17	HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors 1998 ·AIDS ·Schlomo Staszewski, Ralph DeMasi, Andrew Hill, (unknown)	50
18	Variability in Repeated Consecutive Measurements of Plasma Human Immunodeficiency Virus RNA in Persons Receiving Stable Nucleoside Reverse Transcriptase Inhibitor Therapy or No Treatment 1998 ·The Journal of Infectious Diseases ·John Bartlett, Ralph DeMasi, (unknown), Andrew Hill	19
19	STATISTICAL MODELS AND ASYMPTOTIC RESULTS FOR MULTIVARIATE FAILURE TIME DATA WITH GENERALIZED COMPETING RISKS 1997 ·Ralph DeMasi, Bahjat F. Qaqish, Pranab Kumar Sen	2
20	An evaluation of pre- and postoperative nonsteroidal antiinflammatory drugs in patients undergoing knee arthroscopy 1993 ·The American Journal of Sports Medicine ·William E. Nelson, Richard C. Henderson, Louis C. Almekinders, Ralph DeMasi, Timothy N. Taft	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact